Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell.
Health Professionals
Wide local excision, Mohs remain primary treatment options for positive tumor margins
Positive margins are infrequent following standard excision, but when they do occur it is mostly in the upper extremities.
Quick Chat About Skin Cancer with Yale Dermatologist Sean Christensen
Skin cancer is the most common type of cancer in the United States, with millions of cases diagnosed each year. According to the National Institutes of Health (NIH), basal cell carcinoma and squamous cell carcinoma are the most frequently occurring forms, with over 4 million and 1 million cases annually, respectively.
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Oslo, Norway, November 6, 2024 – Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.